Author Archive for: Michael Gorin

About Michael Gorin

This author has yet to write their bio.
Meanwhile lets just say that we are proud Michael Gorin contributed a whooping 3 entries.

Entries by Michael Gorin

Editorial: Preoperative PSMA‐targeted PET imaging: more than just a tool for prostate cancer staging?

The presence of lymph node metastases at the time of prostate cancer diagnosis has significant implications for treatment. According to current guidelines from the National Comprehensive Cancer Network, men with positive lymph nodes on initial staging imaging should be offered treatment with androgen deprivation (± abiraterone) along with consideration for external beam radiation therapy [1]. […]

Editorial: Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer

In the field of oncology, positron emission tomography (PET) is most commonly performed using 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG), a radiofluorinated glucose analogue that accumulates in cells undergoing aerobic glycolysis. Unfortunately, because of the low glycolytic activity of hormone-naïve prostate cancer cells, 18F-FDG PET has been of little value in imaging men with this malignancy [1]. Instead, clinicians have been […]

Editorial: PSMA-targeted imaging of PCa – the best is yet to come

In recent years there has been increasing interest in imaging recurrent or metastatic prostate cancer with positron-emission tomography (PET) radiotracers targeting prostate-specific membrane antigen (PSMA [1]). The majority of this work has been performed using urea-based small molecules labelled with gallium-68 (68Ga). Within this class of radiotracers, 68Ga-PSMA-11 (also known as 68Ga-PSMA-HBED-CC) has been the […]

© 2021 BJU International. All Rights Reserved.